Abbott and Google Health have entered a multi-year collaboration aimed at bringing ongoing glucose monitoring and AI-driven health guidance to users of the Google Health app.
The partnership will see data from Abbott’s Lingo biowearable integrated with software and technology developed by Google Health, allowing users to access a more comprehensive view of their personal health.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As part of the agreement, the two companies plan to launch a large-scale research study to inform both Google Health’s AI-powered coaching features and the ongoing development of Lingo devices.
The study will incorporate continuous glucose, laboratory, wearable and survey data, with the goal of improving understanding of how activity, sleep, well-being and metabolic health are connected.
Abbott’s over-the-counter continuous glucose monitor, Lingo, is designed for adults who are not using insulin.
It enables users to track how factors such as nutrition, physical activity, sleep and stress affect their glucose levels.
By integrating Lingo’s glucose data with the Google Health app, the companies intend to provide users with more targeted and personalised health suggestions.
The Google Health Coach function will use these metabolic insights to deliver recommendations to help with habits around nutrition, activity, sleep and recovery.
The integration is expected to allow users to view their glucose data alongside other health and wellness metrics in a single experience within the app.
Abbott Lingo business divisional vice-president Olivier Ropars said: “The biggest challenge in healthcare isn’t treating disease—it’s helping people stay healthier longer. Abbott’s leadership in biowearables and Google’s expertise in AI and consumer technology create a powerful opportunity to make personalised insights available at unprecedented scale.
“Additionally, we are advancing metabolic health research through one of the largest real-world studies of its kind, generating new insights into the relationship between glucose and everyday behaviours.”
Last month, Abbott begun the TREAT TR study, to assess the safety and performance of its TriClip transcatheter edge-to-edge repair (TEER) system for patients with tricuspid regurgitation, also referred to as a leaky tricuspid valve.
